Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Total Liabilities (2018 - 2025)

Historic Total Liabilities for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $11.6 million.

  • ImmunoTech's Total Liabilities rose 838.33% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 838.33%. This contributed to the annual value of $9.9 million for FY2024, which is 856.02% up from last year.
  • According to the latest figures from Q3 2025, ImmunoTech's Total Liabilities is $11.6 million, which was up 838.33% from $10.7 million recorded in Q2 2025.
  • In the past 5 years, ImmunoTech's Total Liabilities ranged from a high of $11.6 million in Q3 2025 and a low of $3.5 million during Q2 2023
  • Its 3-year average for Total Liabilities is $9.2 million, with a median of $10.0 million in 2024.
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 17607.7% in 2024, then plummeted by 1107.1% in 2025.
  • Quarter analysis of 3 years shows ImmunoTech's Total Liabilities stood at $9.1 million in 2023, then grew by 8.56% to $9.9 million in 2024, then rose by 16.53% to $11.6 million in 2025.
  • Its Total Liabilities was $11.6 million in Q3 2025, compared to $10.7 million in Q2 2025 and $10.1 million in Q1 2025.